MD, PhD. Medical School - Universidade Federal de Minas Gerais (UFMG) - Belo Horizonte (MG), Brazil.
PhD, Associate Professor. Medical School - Universidade Federal de Minas Gerais (UFMG) - Belo Horizonte (MG), Brazil.
Acta Cir Bras. 2021 Oct 8;36(8):e360805. doi: 10.1590/ACB360805. eCollection 2021.
The present study aimed at testing a new formulation of mesalazine linked to chondroitin sulfate and its components alone in the treatment of actinic proctitis in rats.
Forty-seven female Wistar rats were submitted to pelvic radiation and divided into eight groups: control A, mesalazine A, chondroitin A, and conjugate A, gavage of the according substance two weeks after irradiation and sacrifice three weeks after oral treatment; control C, mesalazine C, chondroitin C, and conjugate C, sacrifice six weeks after oral treatment. The rectum was submitted to histological characterization for each of the findings: inflammatory infiltrate, epithelial degeneration, mucosal necrosis, and fibrosis.
The inflammatory infiltrate was more intense in chondroitin A, mesalazine A, and conjugate C. The collagen deposition was less intense in chondroitin A, and mesalazine A, and more intense in control C.
Mesalazine and chondroitin alone were efficacious in inducing a delayed inflammatory response, hence reducing the late fibrosis. The conjugate was able to induce an ever more delayed inflammatory response.
本研究旨在测试一种新型的柳氮磺胺吡啶与硫酸软骨素及其成分的联合制剂,单独应用于治疗放射性直肠炎。
47 只雌性 Wistar 大鼠接受骨盆放射治疗,并分为 8 组:A 组为对照组,A 组给予柳氮磺胺吡啶治疗,A 组给予硫酸软骨素治疗,A 组给予偶联物治疗,照射后两周给予相应药物灌胃,并在口服治疗后 3 周处死;C 组为对照组,C 组给予柳氮磺胺吡啶治疗,C 组给予硫酸软骨素治疗,C 组给予偶联物治疗,口服治疗 6 周后处死。对每个发现进行直肠组织学特征描述:炎症浸润、上皮变性、黏膜坏死和纤维化。
硫酸软骨素 A、柳氮磺胺吡啶 A 和偶联物 C 的炎症浸润更严重。硫酸软骨素 A 和柳氮磺胺吡啶 A 的胶原沉积较弱,而对照组 C 的胶原沉积较强。
柳氮磺胺吡啶和硫酸软骨素单独应用可有效诱导延迟性炎症反应,从而减少晚期纤维化。偶联物能诱导更迟发性的炎症反应。